Have a feature idea you'd love to see implemented?
Let us know!
PLSE Pulse Biosciences Inc
Price (delayed)
$16.12
Market cap
$991.65M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.81
Enterprise value
$920.98M
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX® System is the first
Highlights
PLSE's equity has soared by 193% since the previous quarter and by 52% year-on-year
The quick ratio has surged by 167% since the previous quarter and by 26% year-on-year
PLSE's EPS is up by 9% year-on-year but it is down by 2.5% since the previous quarter
The net income has declined by 17% year-on-year and by 4.8% since the previous quarter
Key stats
What are the main financial stats of PLSE
Market
Valuations
Earnings
Shares outstanding
61.52M
Market cap
$991.65M
Enterprise value
$920.98M
Price to earnings (P/E)
N/A
Price to book (P/B)
12.49
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$47.78M
EBITDA
-$46.59M
Free cash flow
-$34.1M
Per share
Balance sheet
Liquidity
EPS
-$0.81
Free cash flow per share
-$0.56
Book value per share
$1.29
Revenue per share
$0
TBVPS
$1.46
Total assets
$93.05M
Total liabilities
$13.92M
Debt
$8.37M
Equity
$79.13M
Working capital
$73.67M
Debt to equity
0.11
Current ratio
11.93
Quick ratio
11.72
Net debt/EBITDA
1.52
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-76.3%
Return on equity
-98.8%
Return on invested capital
-381%
Return on capital employed
-55.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PLSE stock price
How has the Pulse Biosciences stock price performed over time
Intraday
-0.12%
1 week
-5.79%
1 month
-9.49%
1 year
143.87%
YTD
31.7%
QTD
-8.1%
Financial performance
How have Pulse Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$48.53M
Net income
-$46.13M
Gross margin
N/A
Net margin
N/A
The company's revenue has surged by 100% YoY
The company's gross profit has surged by 100% YoY
The operating income has declined by 22% year-on-year and by 5% since the previous quarter
The net income has declined by 17% year-on-year and by 4.8% since the previous quarter
Growth
What is Pulse Biosciences's growth rate over time
Valuation
What is Pulse Biosciences stock price valuation
P/E
N/A
P/B
12.49
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
PLSE's EPS is up by 9% year-on-year but it is down by 2.5% since the previous quarter
PLSE's equity has soared by 193% since the previous quarter and by 52% year-on-year
The P/B is 23% below the last 4 quarters average of 16.2 but 4.1% above the 5-year quarterly average of 12.0
The company's revenue has surged by 100% YoY
Efficiency
How efficient is Pulse Biosciences business performance
The ROA has contracted by 39% YoY but it has grown by 7% from the previous quarter
PLSE's return on equity is up by 38% year-on-year and by 10% since the previous quarter
The ROIC has declined by 11% since the previous quarter
Dividends
What is PLSE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PLSE.
Financial health
How did Pulse Biosciences financials performed over time
The quick ratio has surged by 167% since the previous quarter and by 26% year-on-year
PLSE's current ratio has soared by 161% from the previous quarter and by 26% YoY
The company's debt is 89% lower than its equity
PLSE's equity has soared by 193% since the previous quarter and by 52% year-on-year
The debt to equity has plunged by 66% from the previous quarter and by 39% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.